Neovasc (NSDQ:NVCN) said yesterday it will initiate a 1-for-100 reverse stock split on Friday as it looks to meet the Nasdaq stock market’s minimum bid price requirement. Through the split, the Vancouver-based company will put a single share of its common stock into the hands of each shareholder for every 100 shares they currently possess. The […]
Neovasc talks note holders into another year, announces 1-for-100 reverse stock split
Neovasc (NSDQ:NVCN) said today that holders of its senior secured convertible notes, originally due May 17, 2019, have agreed to extend the maturity of the notes from next year to May 17, 2020, and said yesterday it will initiate a reverse stock split as it looks to regain compliance with minimum bid price requirement of the […]
Shares in Neovasc fall as Q2 shows growing losses
Shares in Neovasc (NSDQ:NVCN) fell today after the medical device maker posted second quarter earnings that showed growing losses. The Vancouver-based company posted losses of $49.1 million, or 4¢ per share, on sales of $405,247 for the three months ended June 30, seeing losses increase a staggering 1032% while sales shrunk 68.9% compared with the same period […]
Neovasc touts Reducer study data
Neovasc (NSDQ:NVCN) today touted results from a study of its Reducer device designed for treating refractory angina. The Reducer system is designed to alter blood flow in the heart’s circulatory system to increase perfusion of oxygenated blood to ischemic areas of heart muscle, and can be placed in a minimally invasive transvenous procedure, the Vancouver-based company said. […]
Neovasc touts first US implantation of Reducer angina device
Neovasc (NSDQ:NVCN) said today that its Reducer device designed for treating refractory angina was used in its first procedure in the US. The Reducer system is designed to alter blood flow in the heart’s circulatory system to increase perfusion of oxygenated blood to ischemic areas of heart muscle, and can be placed in a minimally invasive transvenous […]
EuroPCR Roundup: Biotronik touts two-year study comparing drug-eluting stents
Biotronik yesterday presented two-year data from a trial comparing Boston Scientific‘s (NYSE:BSX) Synergy biodegradable polymer everolimus-eluting stent, Biotronik’s Orsiro sirolimus-eluting stent and Medtronic‘s (NYSE:MDT) Resolute Integrity zotarolimus-eluting stent. Results from the 3,514-patient trial showed no significant difference between the various stents regarding the rate of target vessel failure after two years. But analyses of one-year data found differences between the rates of […]
8 companies commercializing transcatheter mitral valve replacements
Transcatheter mitral valve replacement is a new frontier in the cardio device field, with big legacy medical device companies including Edwards Lifesciences, Medtronic and Abbott spending hundreds of millions of dollars on companies in the space. Much different from transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR) has been mostly experimental. TMVR is used […]
Neovasc continues pursuit of 1-for-100 reverse stock split
Neovasc (NSDQ:NVCN) said today that it will proceed with plans for a reverse stock split with a ratio of up to 1-for-100, with board members and management urging shareholders to vote for the proposal at an upcoming special meeting. The Vancouver-based company will vote on the proposition on June 4, according to a recently posted SEC […]
Neovasc shares down on Q1 miss, plans 1-for-100 reverse split
Shares in Neovasc (NSDQ:NVCN) have fallen today after the medical device maker missed Wall Street expectations and posted growing losses in its first quarter earnings release, alongside plans for a 1-for-100 reverse split. The Vancouver-based company posted losses of $55.5 million, or 38¢ per share, on sales of $339,922 for the three months ended March 31, […]
Neovasc raises $7m in warrants offering
Neovasc (NSDQ:NVCN) said today that it raised more than $7 million in a warrants offering. Vancouver-based Neovasc said the offering, of nearly 4.9 million Series C warrants at an exercise price of $1.46 apiece, resulted in gross proceeds of $7.1 million. “This receipt into treasury is significant. We believe it is sufficient to substantially fund the […]
NeoVasc shares tumble on 2017 earnings release, sales slide nearly 50%
Shares in Neovasc (NSDQ:NVCN) have fallen nearly 50% today after the structural heart device maker posted shrinking sales in its 2017 earnings release and updated on progress with its investigational Tiara mitral valve replacement. The Vancouver-based company posted losses of $22.9 million, or 28¢ per share, on sales of $5.4 million for the full 2017 year, […]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 7
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube